Encephalitis resident survival guide: Difference between revisions
MoisesRomo (talk | contribs) No edit summary |
No edit summary |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0"; | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align=center| {{fontcolor|#2B3B44|Encephalitis Resident Survival Guide Microchapters}} | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Overview|Overview]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Causes|Causes]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Diagnosis|Diagnosis]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Treatment|Treatment]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Do's|Do's]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Encephalitis resident survival guide#Don'ts|Don'ts]] | |||
|} | |||
{{CMG}}; {{AE}}[https://www.wikidoc.org/index.php/User:MoisesRomo Moises Romo M.D.] | {{CMG}}; {{AE}}[https://www.wikidoc.org/index.php/User:MoisesRomo Moises Romo M.D.] | ||
Line 68: | Line 85: | ||
{{Family tree | |`|-| E01 | | |)|-| E02 | | |)|-| E03 | | | | | |)|-| E04 | | |)|-| E05 | | |)|-| E06 |E01=Immunocompromised:<br>• CMV PCR<br>• HHV6/7 PCR<br>• HIV PCR (CSF)<br>• Toxoplasma gondii serology and/or PCR<br>• MTB testing<br>• Fungal testing<br>• WNV testing |E02=Africa:<br>• Malaria (blood smear)<br>• Trypanosomiasias (blood/CSF smear<br>• Serology from serum and CSF)<br>• Dengue testing |E03=Summer/Fall:<br>• Arbovirusd and tick-borne disease testing |E04=Psychotic features or movement disorder:<br>• Anti-NMDAR antibody (serum, CSF)<br>• Rabies testing<br>• Screen for malignancy<br>• Creutzfeld-Jakobs disease |E05=Elevated transaminases:<br>• Rickettsia serology<br>• Tick borne diseases testing |E06=Frontal lobe:<br>• Naegleria fowleri testing (CSF wet mount and PCRg) }} | {{Family tree | |`|-| E01 | | |)|-| E02 | | |)|-| E03 | | | | | |)|-| E04 | | |)|-| E05 | | |)|-| E06 |E01=Immunocompromised:<br>• CMV PCR<br>• HHV6/7 PCR<br>• HIV PCR (CSF)<br>• Toxoplasma gondii serology and/or PCR<br>• MTB testing<br>• Fungal testing<br>• WNV testing |E02=Africa:<br>• Malaria (blood smear)<br>• Trypanosomiasias (blood/CSF smear<br>• Serology from serum and CSF)<br>• Dengue testing |E03=Summer/Fall:<br>• Arbovirusd and tick-borne disease testing |E04=Psychotic features or movement disorder:<br>• Anti-NMDAR antibody (serum, CSF)<br>• Rabies testing<br>• Screen for malignancy<br>• Creutzfeld-Jakobs disease |E05=Elevated transaminases:<br>• Rickettsia serology<br>• Tick borne diseases testing |E06=Frontal lobe:<br>• Naegleria fowleri testing (CSF wet mount and PCRg) }} | ||
{{Family tree | | | | | | | | |!| | | | | | |!| | | | | | | | | |!| | | | | | |!| | | | | | |!| | }} | {{Family tree | | | | | | | | |!| | | | | | |!| | | | | | | | | |!| | | | | | |!| | | | | | |!| | }} | ||
{{Family tree | | | | | | | | |)|-| E02 | | |)|-| E03 | | | | | |)|-| E04 | | |)|-| E05 | | |)|-| E06 | |E02=Asia:<br>• Japanese encephalitis virus testing<br>• Dengue testing<br>• Malaria (blood smear)<br>• Nipah virus testing|E03=Cat exposure (particularly if with seizures, paucicellular CSF):<br>• Bartonella antibody (serum), ophthalmologic evaluation |E04=Prominent limbic symptoms:<br>• Autoimmune limbic encephalitis testing<br>• HHV6/7 PCR (CSF)<br>• Screen for malignancy |E05=CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset:<br>• | {{Family tree | | | | | | | | |)|-| E02 | | |)|-| E03 | | | | | |)|-| E04 | | |)|-| E05 | | |)|-| E06 | |E02=Asia:<br>• Japanese encephalitis virus testing<br>• Dengue testing<br>• Malaria (blood smear)<br>• Nipah virus testing|E03=Cat exposure (particularly if with seizures, paucicellular CSF):<br>• Bartonella antibody (serum), ophthalmologic evaluation |E04=Prominent limbic symptoms:<br>• Autoimmune limbic encephalitis testing<br>• HHV6/7 PCR (CSF)<br>• Screen for malignancy |E05=CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset:<br>• MTB testingb<br>• Fungal testing |E06=Temporal lobe:<br>• VGKC antibodies (serum and CSF)<br>• HHV 6/7 PCR (CSF) }} | ||
{{Family tree | | | | | | | | |!| | | | | | |!| | | | | | | | | |!| | | | | | |!| | | | | | |!| | }} | {{Family tree | | | | | | | | |!| | | | | | |!| | | | | | | | | |!| | | | | | |!| | | | | | |!| | }} | ||
{{Family tree | | | | | | | | |)|-| E01 | | |)|-| E02 | | | | | |)|-| E03 | | |)|-| E04 | | |)|-| E05 | | |E01=Australia:<br>• Murray Valley encephalitis virus testingd<br>• Kunjin virus testingd<br>• Australian Bat Lyssavirus (ABLV) testing |E02=Tick exposure:<br>• Tick borne disease testing |E03=Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas):<br>• Rabies testing |E04=CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use:<br>• CSF PCR for S. pneumoniae and N. meningiditis |E05=Basal ganglia and/or thalamus:<br>• Arbovirusd testing<br>• MTB testing }} | {{Family tree | | | | | | | | |)|-| E01 | | |)|-| E02 | | | | | |)|-| E03 | | |)|-| E04 | | |)|-| E05 | | |E01=Australia:<br>• Murray Valley encephalitis virus testingd<br>• Kunjin virus testingd<br>• Australian Bat Lyssavirus (ABLV) testing |E02=Tick exposure:<br>• Tick borne disease testing |E03=Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas):<br>• Rabies testing |E04=CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use:<br>• CSF PCR for S. pneumoniae and N. meningiditis |E05=Basal ganglia and/or thalamus:<br>• Arbovirusd testing<br>• MTB testing }} | ||
Line 87: | Line 104: | ||
| | | | ||
===Diagnostic Criteria for Encephalitis and Encephalopathy of Presumed Infectious or Autoimmune Etiology according to the International Encephalitis Consortium=== | ===Diagnostic Criteria for Encephalitis and Encephalopathy of Presumed Infectious or Autoimmune Etiology according to the International Encephalitis Consortium=== | ||
|- | |- | ||
| colspan="1" rowspan="1" |'''Major Criterion (required):''' | | colspan="1" rowspan="1" |'''Major Criterion (required):''' | ||
Line 123: | Line 127: | ||
==Treatment== | ==Treatment== | ||
Shown below is an algorithm summarizing treatment of herpetic encephalitis according to the Glasgow Institute of Neurological Sciences guidelines:<ref name="Kennedy20042">{{cite journal|last1=Kennedy|first1=P G E|title=VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=75|issue=90001|year=2004|pages=10i–15|issn=0022-3050|doi=10.1136/jnnp.2003.034280}}</ref> | Shown below is an algorithm summarizing treatment of herpetic encephalitis according to the Glasgow Institute of Neurological Sciences guidelines:<ref name="Kennedy20042">{{cite journal|last1=Kennedy|first1=P G E|title=VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=75|issue=90001|year=2004|pages=10i–15|issn=0022-3050|doi=10.1136/jnnp.2003.034280}}</ref><br><br> | ||
{{Family tree/start}} | |||
{{Family tree | | | | A01 |-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-| A02 | |A01= Suspected Herpes Simplex Encephalitis (HSE)| A02= Administer Acyclovir}} | |||
{{Family tree | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|+|-|-|-|.| }} | |||
{{Family tree | | | | A01 |-|-| A02 | | | | | | | | | | | | | | | | | | | | A03 | | A04 | | A05 | |A01=CT/MRI scan |A02=No mass but severe edema |A03=HSE proven<br>• 14-day course |A04=Possible HSE<br>• 10-day course |A05=Other diagnosis<br>• Stop acyclovir }} | |||
{{Family tree | | | | |!| | | | |!| | | }} | |||
{{Family tree | | | | A01 | | | |!| | |A01=No mass or severe edema }} | |||
{{Family tree | | | | |!| | | | |!| | | }} | |||
{{Family tree | | | | A01 |-|-| A02 |A01=Lumbar puncture |A02=Manitol and/or steroids }} | |||
{{Family tree | | | | |!| | | | | | | }} | |||
{{Family tree | | | | A01 | | | | | |A01=Supportive or alternative diagnosis }} | |||
{{Family tree/end}} | |||
<br><br> | |||
== | ==Dos== | ||
*Rule | *Rule out other causes of decreased level of [[consciousness]] and [[Personality changes|personality change]], such as [[drug abuse]].<ref name="Kennedy2004">{{cite journal|last1=Kennedy|first1=P G E|title=VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=75|issue=90001|year=2004|pages=10i–15|issn=0022-3050|doi=10.1136/jnnp.2003.034280}}</ref> | ||
*Take a | *Take a careful history examination of relatives when managing a comatose patient.<ref name="TunkelGlaser20082">{{cite journal|last1=Tunkel|first1=Allan R.|last2=Glaser|first2=Carol A.|last3=Bloch|first3=Karen C.|last4=Sejvar|first4=James J.|last5=Marra|first5=Christina M.|last6=Roos|first6=Karen L.|last7=Hartman|first7=Barry J.|last8=Kaplan|first8=Sheldon L.|last9=Scheld|first9=W. Michael|last10=Whitley|first10=Richard J.|title=The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|volume=47|issue=3|year=2008|pages=303–327|issn=1537-6591|doi=10.1086/589747}}</ref> | ||
*Perform routine full [[haematological]] and [[biochemical]] [[blood]] screen.<ref name="VenkatesanTunkel2013" /> | *Perform routine full [[haematological]] and [[biochemical]] [[blood]] screen.<ref name="VenkatesanTunkel2013" /> | ||
*When performing a [[CSF]] [[analysis]], collect at least 20 ml, if possible; freeze at least 5-10 ml fluid; document opening pressure, [[WBC]] count with differential, [[RBC]] count, [[protein]], and [[glucose]]; [[Gram stain]] and [[Bacterial cultures|bacterial culture]].<ref name="VenkatesanTunkel2013" /> | *When performing a [[CSF]] [[analysis]], collect at least 20 ml, if possible; freeze at least 5-10 ml fluid; document opening pressure, [[WBC]] count with differential, [[RBC]] count, [[protein]], and [[glucose]]; [[Gram stain]] and [[Bacterial cultures|bacterial culture]].<ref name="VenkatesanTunkel2013" /> | ||
*Be aware that the | *Be aware that the absence of [[leukocytosis]], focal [[neurological]] [[signs]], [[fever]], [[headache]], and [[pleocytosis]], is more suggestive of [[encephalopathy]] rather than [[encephalitis]].<ref name="TunkelGlaser20082" /> | ||
*Perform a [[PCR]] for [[HSV|HSV-1/2]], [[VZV]], and [[enterovirus]] [[viruses]].<ref name="WeilGlaser2002">{{cite journal|last1=Weil|first1=Ana A.|last2=Glaser|first2=Carol A.|last3=Amad|first3=Zahwa|last4=Forghani|first4=Bagher|title=Patients with Suspected Herpes Simplex Encephalitis: Rethinking an Initial Negative Polymerase Chain Reaction Result|journal=Clinical Infectious Diseases|volume=34|issue=8|year=2002|pages=1154–1157|issn=1058-4838|doi=10.1086/339550}}</ref><ref name="KoskiniemiRantalaiho2001">{{cite journal|last1=Koskiniemi|first1=Marjaleena|last2=Rantalaiho|first2=Timo|last3=Piiparinen|first3=Heli|last4=von Bonsdorff|first4=Carl-Henrik|last5=Färkkilä|first5=Markus|last6=Järvinen|first6=Asko|last7=Kinnunen|first7=Esko|last8=Koskiniemi|first8=Suvi|last9=Mannonen|first9=Laura|last10=Muttilainen|first10=Marketta|last11=Linnavuori|first11=Kimmo|last12=Porras|first12=Jukka|last13=Puolakkainen|first13=Mirja|last14=Räihä|first14=Kirsti|last15=Salonen|first15=Eeva-Marjatta|last16=Ukkonen|first16=Pentti|last17=Vaheri|first17=Antti|last18=Valtonen|first18=Villei|title=Infections of the central nervous system of suspected viral origin: A collaborative study from Finland|journal=Journal of Neurovirology|volume=7|issue=5|year=2001|pages=400–408|issn=1355-0284|doi=10.1080/135502801753170255}}</ref> | *Perform a [[PCR]] for [[HSV|HSV-1/2]], [[VZV]], and [[enterovirus]] [[viruses]].<ref name="WeilGlaser2002">{{cite journal|last1=Weil|first1=Ana A.|last2=Glaser|first2=Carol A.|last3=Amad|first3=Zahwa|last4=Forghani|first4=Bagher|title=Patients with Suspected Herpes Simplex Encephalitis: Rethinking an Initial Negative Polymerase Chain Reaction Result|journal=Clinical Infectious Diseases|volume=34|issue=8|year=2002|pages=1154–1157|issn=1058-4838|doi=10.1086/339550}}</ref><ref name="KoskiniemiRantalaiho2001">{{cite journal|last1=Koskiniemi|first1=Marjaleena|last2=Rantalaiho|first2=Timo|last3=Piiparinen|first3=Heli|last4=von Bonsdorff|first4=Carl-Henrik|last5=Färkkilä|first5=Markus|last6=Järvinen|first6=Asko|last7=Kinnunen|first7=Esko|last8=Koskiniemi|first8=Suvi|last9=Mannonen|first9=Laura|last10=Muttilainen|first10=Marketta|last11=Linnavuori|first11=Kimmo|last12=Porras|first12=Jukka|last13=Puolakkainen|first13=Mirja|last14=Räihä|first14=Kirsti|last15=Salonen|first15=Eeva-Marjatta|last16=Ukkonen|first16=Pentti|last17=Vaheri|first17=Antti|last18=Valtonen|first18=Villei|title=Infections of the central nervous system of suspected viral origin: A collaborative study from Finland|journal=Journal of Neurovirology|volume=7|issue=5|year=2001|pages=400–408|issn=1355-0284|doi=10.1080/135502801753170255}}</ref> | ||
*[[RPR]] is | *[[RPR]] is preferred over [[VDRL]] for [[Treponemal infection|treponemal]] detection.<ref name="VenkatesanTunkel2013" /><ref name="TunkelGlaser20082" /> | ||
*[[MRI]] is | *[[MRI]] is preferred over [[CT scan]] for [[neuroimaging]].<ref name="VenkatesanTunkel2013" /> | ||
*When significant [[edema]] is present in [[imaging]], give [[steroids]] and/or [[mannitol]] to reduce the [[intracranial pressure]] before [[lumbar puncture]].<ref name="TunkelGlaser20082" /><br /> | *When significant [[edema]] is present in [[imaging]], give [[steroids]] and/or [[mannitol]] to reduce the [[intracranial pressure]] before [[lumbar puncture]].<ref name="TunkelGlaser20082" /><br /> | ||
Line 144: | Line 160: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Up-To-Date]] |
Latest revision as of 20:17, 19 February 2021
Encephalitis Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.
Synonyms and Keywords: encephalitis management, encephalitis workup, encephalitis approach,encephalitis management, encephalitis treatment, encephalitis diagnosis
Overview
Encephalitis refers to the inflammation of the brain parenchyma acompanied of neurological dysfunction. The causes of encephalitis are mostly infectious, being viruses, bacteria, fungi, or parasites the possible agents. Presentation usually involves headache, fever, confusion, neck stiffness (Kernig and Brudzinski signs), and vomiting. Diagnosis is typically based on clinical presentation and supported by blood tests, medical imaging, and analysis of cerebrospinal fluid. Rapid identification of encephalitis is crucial to reduce sequelae. Management is directed against the affecting agent (antivirals, antibiotics), reducing swelling, and supportive measures.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- All causes of encephalitis may be potentially fatal or disabiling if left untreated in 24 hours; among them:
Common Causes
Diagnosis
Shown below is an algorithm summarizing the diagnosis of encephalitis according to the International Encephalitis Consortium guidelines:[1]
Patient suspicious for encephalitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PERFORM: • CSF analysis • Routine blood testing • Blood cultures • HSV-1/2 PCR • VZV PCR • Enterovirus PCR • Cryptococcal antigen and/or India Ink staining • Oligoclonal bands and IgG index • VDRL • HIV serology • Hold acute serum and collect convalescent serum 10–14 d later for paired antibody testing • Neuroimaging (MRI preferred to CT, if available) • Chest imaging (Chest x-ray and/or CT) • EEG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate further testing if additional risk factors are present | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Host factors | Geographic factors | Season and exposure | Specific signs and symptoms | Laboratory features | Neuroimaging features | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunocompromised: • CMV PCR • HHV6/7 PCR • HIV PCR (CSF) • Toxoplasma gondii serology and/or PCR • MTB testing • Fungal testing • WNV testing | Africa: • Malaria (blood smear) • Trypanosomiasias (blood/CSF smear • Serology from serum and CSF) • Dengue testing | Summer/Fall: • Arbovirusd and tick-borne disease testing | Psychotic features or movement disorder: • Anti-NMDAR antibody (serum, CSF) • Rabies testing • Screen for malignancy • Creutzfeld-Jakobs disease | Elevated transaminases: • Rickettsia serology • Tick borne diseases testing | Frontal lobe: • Naegleria fowleri testing (CSF wet mount and PCRg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asia: • Japanese encephalitis virus testing • Dengue testing • Malaria (blood smear) • Nipah virus testing | Cat exposure (particularly if with seizures, paucicellular CSF): • Bartonella antibody (serum), ophthalmologic evaluation | Prominent limbic symptoms: • Autoimmune limbic encephalitis testing • HHV6/7 PCR (CSF) • Screen for malignancy | CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset: • MTB testingb • Fungal testing | Temporal lobe: • VGKC antibodies (serum and CSF) • HHV 6/7 PCR (CSF) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Australia: • Murray Valley encephalitis virus testingd • Kunjin virus testingd • Australian Bat Lyssavirus (ABLV) testing | Tick exposure: • Tick borne disease testing | Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas): • Rabies testing | CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use: • CSF PCR for S. pneumoniae and N. meningiditis | Basal ganglia and/or thalamus: • Arbovirusd testing • MTB testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Europe: • Tick-borne encephalitis virus (serology) | Animal bite/bat exposure: • Rabies testing | Respiratory symptoms: • Mycoplasma pneumoniae serology and throat PCR (if either positive, then do CSF PCR) • Respiratory virus testing | CSF eosinophilia: • MTB testingb • Fungal testingc • Baylisascaris procyonis antibody (serum) • Angiostrongylus cantonensis and Gnathostomasp. testing | Brainstem: • Arbovirus testingd • Listeria PCR(if available) • Brucella antibody (serum) • MTB testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Southern Europe: • WNV testing • Toscana virus testing | Swimming or diving in warm freshwater or nasal/sinus irrigation: • Naegleria fowleri (CSF wet mount and PCR) | Acute flaccid paralysis: • Arbovirus testingd • Rabies testing | RBCs in CSF: • Naegleria fowleri testing | Cerebellum: • EBV PCR (CSF) and serology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Central and South America: • Dengue testingd • Malaria (blood smear) • WNV • Venezuelan equine encephalitis testing | Parkinsonism: • Arbovirus testingd • Toxoplasma serology | Hyponatremia—anti: • VGKC antibody (serum) • MTB testing | Diffuse cerebral edema: • Respiratory virus testing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
North America: • Geographically appropriate arboviral testing (eg, WNV, Powassan, LaCrosse, Eastern Equine Encephalitis virusesd, Lyme(serum ELISA and Western blot) | Nonhealing skin lesions: • Balamuthia mandrillaris • Acanthamoeba testing | Space occupying and/or ring-enhancing lesions: • MTB testingb • Fungal testingc • Balamuthia mandrillaris and Acanthamoeba testingg • Toxoplasma serology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrocephalus and/or basilar meningeal enhancement: • MTB testingb • Fungal testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Infarction or hemorrhage: • MTB testing • Fungal testing • Respiratory virus testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic Criteria for Encephalitis and Encephalopathy of Presumed Infectious or Autoimmune Etiology according to the International Encephalitis Consortium |
Major Criterion (required): |
Patients presenting to medical attention with altered mental status (defined as decreased or altered level of consciousness, lethargy, or personality change) lasting ≥24 h with no alternative cause identified. |
Minor Criteria (2 required for possible encephalitis; ≥3 required for probable or confirmeda encephalitis): |
Documented fever ≥38° C (100.4°F) within the 72 h before or after presentation. |
Generalized or partial seizures not fully attributable to a preexisting seizure disorder. |
New onset of focal neurologic findings. |
CSF WBC count ≥5/cubic mm. |
Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior studies or appears acute in onset. |
Abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause. |
Do not modify |
Treatment
Shown below is an algorithm summarizing treatment of herpetic encephalitis according to the Glasgow Institute of Neurological Sciences guidelines:[2]
Suspected Herpes Simplex Encephalitis (HSE) | Administer Acyclovir | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CT/MRI scan | No mass but severe edema | HSE proven • 14-day course | Possible HSE • 10-day course | Other diagnosis • Stop acyclovir | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No mass or severe edema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lumbar puncture | Manitol and/or steroids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supportive or alternative diagnosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dos
- Rule out other causes of decreased level of consciousness and personality change, such as drug abuse.[3]
- Take a careful history examination of relatives when managing a comatose patient.[4]
- Perform routine full haematological and biochemical blood screen.[1]
- When performing a CSF analysis, collect at least 20 ml, if possible; freeze at least 5-10 ml fluid; document opening pressure, WBC count with differential, RBC count, protein, and glucose; Gram stain and bacterial culture.[1]
- Be aware that the absence of leukocytosis, focal neurological signs, fever, headache, and pleocytosis, is more suggestive of encephalopathy rather than encephalitis.[4]
- Perform a PCR for HSV-1/2, VZV, and enterovirus viruses.[5][6]
- RPR is preferred over VDRL for treponemal detection.[1][4]
- MRI is preferred over CT scan for neuroimaging.[1]
- When significant edema is present in imaging, give steroids and/or mannitol to reduce the intracranial pressure before lumbar puncture.[4]
Don'ts
- Do not delay antiviral treatment, since mortality may reach up to 70% when not given.[3][7]
- Do no perform lumbar puncture before neuroimaging.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Venkatesan, A.; Tunkel, A. R.; Bloch, K. C.; Lauring, A. S.; Sejvar, J.; Bitnun, A.; Stahl, J-P.; Mailles, A.; Drebot, M.; Rupprecht, C. E.; Yoder, J.; Cope, J. R.; Wilson, M. R.; Whitley, R. J.; Sullivan, J.; Granerod, J.; Jones, C.; Eastwood, K.; Ward, K. N.; Durrheim, D. N.; Solbrig, M. V.; Guo-Dong, L.; Glaser, C. A.; Sheriff, Heather; Brown, David; Farnon, Eileen; Messenger, Sharon; Paterson, Beverley; Soldatos, Ariane; Roy, Sharon; Visvesvara, Govinda; Beach, Michael; Nasci, Roger; Pertowski, Carol; Schmid, Scott; Rascoe, Lisa; Montgomery, Joel; Tong, Suxiang; Breiman, Robert; Franka, Richard; Keuhnert, Matt; Angulo, Fred; Cherry, James (2013). "Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium". Clinical Infectious Diseases. 57 (8): 1114–1128. doi:10.1093/cid/cit458. ISSN 1537-6591.
- ↑ Kennedy, P G E (2004). "VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT". Journal of Neurology, Neurosurgery & Psychiatry. 75 (90001): 10i–15. doi:10.1136/jnnp.2003.034280. ISSN 0022-3050.
- ↑ 3.0 3.1 Kennedy, P G E (2004). "VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT". Journal of Neurology, Neurosurgery & Psychiatry. 75 (90001): 10i–15. doi:10.1136/jnnp.2003.034280. ISSN 0022-3050.
- ↑ 4.0 4.1 4.2 4.3 4.4 Tunkel, Allan R.; Glaser, Carol A.; Bloch, Karen C.; Sejvar, James J.; Marra, Christina M.; Roos, Karen L.; Hartman, Barry J.; Kaplan, Sheldon L.; Scheld, W. Michael; Whitley, Richard J. (2008). "The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 47 (3): 303–327. doi:10.1086/589747. ISSN 1537-6591.
- ↑ Weil, Ana A.; Glaser, Carol A.; Amad, Zahwa; Forghani, Bagher (2002). "Patients with Suspected Herpes Simplex Encephalitis: Rethinking an Initial Negative Polymerase Chain Reaction Result". Clinical Infectious Diseases. 34 (8): 1154–1157. doi:10.1086/339550. ISSN 1058-4838.
- ↑ Koskiniemi, Marjaleena; Rantalaiho, Timo; Piiparinen, Heli; von Bonsdorff, Carl-Henrik; Färkkilä, Markus; Järvinen, Asko; Kinnunen, Esko; Koskiniemi, Suvi; Mannonen, Laura; Muttilainen, Marketta; Linnavuori, Kimmo; Porras, Jukka; Puolakkainen, Mirja; Räihä, Kirsti; Salonen, Eeva-Marjatta; Ukkonen, Pentti; Vaheri, Antti; Valtonen, Villei (2001). "Infections of the central nervous system of suspected viral origin: A collaborative study from Finland". Journal of Neurovirology. 7 (5): 400–408. doi:10.1080/135502801753170255. ISSN 1355-0284.
- ↑ Whitley, Richard J; Gnann, John W (2002). "Viral encephalitis: familiar infections and emerging pathogens". The Lancet. 359 (9305): 507–513. doi:10.1016/S0140-6736(02)07681-X. ISSN 0140-6736.